TWI893097B - 用於治療癌症之米達替尼與利非芬尼之共同投藥 - Google Patents

用於治療癌症之米達替尼與利非芬尼之共同投藥

Info

Publication number
TWI893097B
TWI893097B TW110112271A TW110112271A TWI893097B TW I893097 B TWI893097 B TW I893097B TW 110112271 A TW110112271 A TW 110112271A TW 110112271 A TW110112271 A TW 110112271A TW I893097 B TWI893097 B TW I893097B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
per day
administered
Prior art date
Application number
TW110112271A
Other languages
English (en)
Chinese (zh)
Other versions
TW202207910A (zh
Inventor
羅侶松
湯志宇
巴德雷丁 愛迪斯
陶德 偉伯司特 席拉爾
Original Assignee
開曼群島商百濟神州有限公司
美商斯普林渥克斯治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 開曼群島商百濟神州有限公司, 美商斯普林渥克斯治療有限公司 filed Critical 開曼群島商百濟神州有限公司
Publication of TW202207910A publication Critical patent/TW202207910A/zh
Application granted granted Critical
Publication of TWI893097B publication Critical patent/TWI893097B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110112271A 2020-04-03 2021-04-02 用於治療癌症之米達替尼與利非芬尼之共同投藥 TWI893097B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063005153P 2020-04-03 2020-04-03
US63/005,153 2020-04-03

Publications (2)

Publication Number Publication Date
TW202207910A TW202207910A (zh) 2022-03-01
TWI893097B true TWI893097B (zh) 2025-08-11

Family

ID=75674969

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112271A TWI893097B (zh) 2020-04-03 2021-04-02 用於治療癌症之米達替尼與利非芬尼之共同投藥

Country Status (21)

Country Link
US (1) US12667560B2 (enExample)
EP (1) EP4125842B1 (enExample)
JP (2) JP7748386B2 (enExample)
KR (1) KR20230048476A (enExample)
CN (1) CN116194095B (enExample)
AU (1) AU2021246141A1 (enExample)
BR (1) BR112022019914A2 (enExample)
CA (1) CA3174223A1 (enExample)
CL (1) CL2022002682A1 (enExample)
CO (1) CO2022015891A2 (enExample)
DK (1) DK4125842T3 (enExample)
ES (1) ES2985012T3 (enExample)
FI (1) FI4125842T3 (enExample)
HU (1) HUE067894T2 (enExample)
IL (1) IL296878A (enExample)
MX (1) MX2022012351A (enExample)
PE (1) PE20231211A1 (enExample)
PL (1) PL4125842T3 (enExample)
PT (1) PT4125842T (enExample)
TW (1) TWI893097B (enExample)
WO (1) WO2021202981A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US20230293464A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of pancreatic ductal adenocarcinoma with mirdametinib
MX2024011403A (es) * 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.
WO2023209611A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
EP4601631A4 (en) * 2022-10-14 2026-04-08 Springworks Therapeutics Inc COMBINATION INTENDED FOR USE IN CANCER TREATMENT

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140155372A1 (en) * 2011-04-01 2014-06-05 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1562601A1 (en) 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
WO2007042885A2 (en) 2005-10-07 2007-04-19 Pfizer Products Inc. Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2016248376B2 (en) 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
WO2019113345A1 (en) 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
MX2024011403A (es) 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.
PE20242177A1 (es) 2022-03-17 2024-11-07 St Jude Childrens Res Hospital Inc Tratamiento del glioma de bajo grado con mirdametinib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140155372A1 (en) * 2011-04-01 2014-06-05 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Zhiyu Tang et al., BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers, Mol Cancer Ther., 14(10), 2015/10/1, pp 2187–2197. *

Also Published As

Publication number Publication date
US20230128315A1 (en) 2023-04-27
IL296878A (en) 2022-12-01
HUE067894T2 (hu) 2024-11-28
ES2985012T3 (es) 2024-11-04
CN116194095A (zh) 2023-05-30
PL4125842T3 (pl) 2024-10-14
EP4125842A1 (en) 2023-02-08
CO2022015891A2 (es) 2023-05-08
JP2023521036A (ja) 2023-05-23
EP4125842B1 (en) 2024-06-05
PT4125842T (pt) 2024-08-06
US12667560B2 (en) 2026-06-30
JP7748386B2 (ja) 2025-10-02
PE20231211A1 (es) 2023-08-17
MX2022012351A (es) 2023-03-13
DK4125842T3 (da) 2024-07-22
FI4125842T3 (fi) 2024-08-06
JP2025120501A (ja) 2025-08-15
CA3174223A1 (en) 2021-10-07
CL2022002682A1 (es) 2023-06-16
KR20230048476A (ko) 2023-04-11
CN116194095B (zh) 2024-09-13
AU2021246141A1 (en) 2022-12-01
TW202207910A (zh) 2022-03-01
BR112022019914A2 (pt) 2022-12-13
WO2021202981A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP7748386B2 (ja) がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与
CN101622013A (zh) 包含丁丙诺啡和纳洛酮的改善的药用组合物
WO2019006050A1 (en) NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION
JP5757544B2 (ja) 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法
JP2024010018A (ja) うつ病を治療するための組成物および方法
Mantz Alpha2-adrenoceptor agonists: analgesia, sedation, anxiolysis, haemodynamics, respiratory function and weaning
US20080161329A1 (en) Pharmaceutical uses
Moyao-García et al. A pilot study of nalbuphine versus tramadol administered through continuous intravenous infusion for postoperative pain control in children
EP3982970A1 (en) New treatment of sma
Arora Prophylactic tramadol versus dexmedetomidine for prevention of shivering during spinal anaesthesia
JP2022520276A (ja) ベンズイミダゾール誘導体化合物を含む医薬組成物
JP6042886B2 (ja) 早漏症治療用の薬学組成物
US12303503B1 (en) Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
HK40116800A (en) Compositions and method for treating depression
JPH10287568A (ja) アルコール依存症治療剤
JP2020172475A (ja) メロキシカム又はその薬学的に許容される塩を含有する内服治療剤
CN106413698A (zh) 耳鸣患者的治疗用药剂
EP1814549A2 (en) Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
HK1219669A1 (en) Dosage form containing oxycodone and naloxone